Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8224624 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2TSHRMAPTMEN1KMT2A | |
| SCHEMBL539077 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2TSHRMAPTMEN1KMT2A | |
| SCHEMBL6718014 | 0.90 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRMAPTMEN1KMT2A | |
| SCHEMBL15587121 | 0.90 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRMAPTMEN1KMT2A | |
| SCHEMBL15587059 | 0.90 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRMAPTMEN1KMT2A | |
| Phosphine SCHEMBL27419558 | 0.89 | SMN1; SMN2 (0.52) | SMN1; SMN2TSHRMAPTMEN1KMT2A | |
| SCHEMBL28578770 | 0.89 | SMN1; SMN2 (0.52) | SMN1; SMN2TSHRMAPTMEN1KMT2A | |
| SCHEMBL28329152 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2TSHRMAPTMEN1KMT2A | |
| SCHEMBL29232860 | 0.86 | TSHR (0.58) | SMN1; SMN2TSHRMEN1KMT2ANPC1 | |
| SCHEMBL29006983 | 0.86 | TSHR (0.58) | SMN1; SMN2TSHRMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | SMN1; SMN2 4563/4885TSHR 1363/4885MAPT 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.